1. Home
  2. GYRE vs VECO Comparison

GYRE vs VECO Comparison

Compare GYRE & VECO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • GYRE
  • VECO
  • Stock Information
  • Founded
  • GYRE 2002
  • VECO 1945
  • Country
  • GYRE United States
  • VECO United States
  • Employees
  • GYRE N/A
  • VECO N/A
  • Industry
  • GYRE Biotechnology: Pharmaceutical Preparations
  • VECO Industrial Machinery/Components
  • Sector
  • GYRE Health Care
  • VECO Technology
  • Exchange
  • GYRE Nasdaq
  • VECO Nasdaq
  • Market Cap
  • GYRE 897.1M
  • VECO 1.0B
  • IPO Year
  • GYRE N/A
  • VECO 1994
  • Fundamental
  • Price
  • GYRE $9.07
  • VECO $19.31
  • Analyst Decision
  • GYRE
  • VECO Buy
  • Analyst Count
  • GYRE 0
  • VECO 7
  • Target Price
  • GYRE N/A
  • VECO $30.43
  • AVG Volume (30 Days)
  • GYRE 332.9K
  • VECO 680.1K
  • Earning Date
  • GYRE 05-09-2025
  • VECO 05-07-2025
  • Dividend Yield
  • GYRE N/A
  • VECO N/A
  • EPS Growth
  • GYRE N/A
  • VECO N/A
  • EPS
  • GYRE 0.02
  • VECO 1.07
  • Revenue
  • GYRE $100,643,000.00
  • VECO $710,109,000.00
  • Revenue This Year
  • GYRE $22.01
  • VECO N/A
  • Revenue Next Year
  • GYRE $88.14
  • VECO $9.72
  • P/E Ratio
  • GYRE $120.95
  • VECO $18.57
  • Revenue Growth
  • GYRE N/A
  • VECO 3.30
  • 52 Week Low
  • GYRE $6.11
  • VECO $16.92
  • 52 Week High
  • GYRE $19.00
  • VECO $49.25
  • Technical
  • Relative Strength Index (RSI)
  • GYRE 45.78
  • VECO 45.85
  • Support Level
  • GYRE $9.26
  • VECO $18.85
  • Resistance Level
  • GYRE $11.61
  • VECO $20.41
  • Average True Range (ATR)
  • GYRE 1.09
  • VECO 0.64
  • MACD
  • GYRE -0.21
  • VECO -0.09
  • Stochastic Oscillator
  • GYRE 28.12
  • VECO 17.23

About GYRE Gyre Therapeutics Inc.

Gyre Therapeutics Inc is a commercial-stage pharmaceutical company developing and commercializing small-molecule anti-inflammatory and anti-fibrotic drugs targeting organ diseases, focusing specifically on organ fibrosis. The company's commercial-stage products include ETUARY, Avatrombopag, and Nintedanib. In addition, it is focused on the development and commercialization of Hydronidone (F351) for the treatment of Metabolic Dysfunction Associated Steatohepatitis (MASH-associated liver fibrosis (MASH fibrosis). Gyre is also advancing a diverse pipeline of different drug candidates in China, including F573, F528, and F230. The company's reportable segments are Gyre Pharmaceuticals, which derives maximum revenue from the sale of ETUARY and certain generic drugs in the PRC, Gyre, and Other.

About VECO Veeco Instruments Inc.

Veeco Instruments Inc is a United States-based company engaged in designing, developing, and manufacturing thin-film process equipment, mainly used for producing electronic devices. The company focuses on semiconductor process equipment that addresses a range of challenging materials engineering problems for our customers. Its products include Laser Processing Systems, Lithography Systems, Ion Beam Systems, SiC CVD Systems, MOCVD Systems, Wet Processing Systems, MBE Technologies, Atomic Layer Deposition Systems, Physical Vapor Deposition Systems, Dicing and Lapping Systems, as well as Gas & Vapor Delivery Systems. The majority of the company's revenue is generated from sales to the Semiconductor Industry and within China.

Share on Social Networks: